TOP-5 Price Targets by Analysts on January 28, 2026
Reading Time: 3 minutes
BridgeBio [US10806X1028] Barclays initiates coverage with "Overweight" and a price target of 157 USD (100% price potential) The responsible analyst is exceptionally optimistic about the development of the biotech sector in 2026. According to his assessment, many biotech stocks remain undervalued despite solid fundamentals, which, combined with a favorable market environment, is expected to create clear opportunities. Barclays anticipates that ongoing mergers and acquisitions will act as a supporting factor, as large pharmaceutical companies continue...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
